Overview

A Study to Compare the Effect of Transipeg 2.95 g or Forlax Junior 4 g in Children With Constipation

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The study design combines a long-term safety and a dose range determination objective. The first 8 weeks of the study were primarily intended for the dose range determination, while the later visits were used for the comparison of long-term safety between the groups.
Phase:
Phase 4
Details
Lead Sponsor:
Bayer